LON:AREC Arecor Therapeutics (AREC) Share Price, News & Analysis GBX 39.10 +0.60 (+1.56%) As of 05/9/2025 10:57 AM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsEarningsHeadlinesBuy This Stock About Arecor Therapeutics Stock (LON:AREC) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Arecor Therapeutics alerts:Sign Up Key Stats Today's Range 38.50▼ 39.1050-Day Range 36▼ 52.3952-Week Range 35.40▼ 170Volume991 shsAverage Volume17,503 shsMarket Capitalization£14.76 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewArecor Therapeutics plc is a globally focused biopharmaceutical company transforming patient care by bringing innovative medicines to market through the enhancement of existing therapeutic products. By applying our innovative proprietary technology platform, Arestat™, we are developing an internal portfolio of proprietary products in diabetes and other indications, as well as working with leading pharmaceutical and biotechnology companies to deliver therapeutic products. The Arestat™ platform is supported by an extensive patent portfolio. For further details please see our website, www.arecor.com Read More… Receive AREC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Arecor Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address AREC Stock News HeadlinesSMALL-CAP MOVERS: Is popping AIM ready to really blow up? One research house reckons soMay 10 at 6:38 AM | uk.investing.comSMALL CAP MOVERS: Is 'oversold' AIM market due a comeback story?May 9 at 8:37 PM | msn.comThis robot is coming to 65 million Americans … this year.Robots are the hottest thing going in tech right now. And they just had a coming-out party in Las Vegas. Everywhere you turned at the Consumer Electronics Show, a robot was there to greet you.May 10, 2025 | Weiss Ratings (Ad)Arecor Therapeutics Full Year 2024 Earnings: Misses ExpectationsApril 23, 2025 | finance.yahoo.comArecor Therapeutics strikes deal for development of peptide therapyMarch 12, 2025 | lse.co.ukArecor Partners to Innovate Peptide Therapy FormulationMarch 12, 2025 | tipranks.comArecor Full Year 2024 Trading UpdateFebruary 4, 2025 | lse.co.ukArecor Therapeutics confident for the future as revenue risesFebruary 3, 2025 | lse.co.ukSee More Headlines AREC Stock Analysis - Frequently Asked Questions How have AREC shares performed this year? Arecor Therapeutics' stock was trading at GBX 73.75 at the beginning of the year. Since then, AREC stock has decreased by 47.0% and is now trading at GBX 39.10. View the best growth stocks for 2025 here. How were Arecor Therapeutics' earnings last quarter? Arecor Therapeutics plc (LON:AREC) announced its quarterly earnings results on Tuesday, April, 22nd. The company reported ($0.31) earnings per share (EPS) for the quarter. Arecor Therapeutics had a negative trailing twelve-month return on equity of 118.67% and a negative net margin of 176.89%. How do I buy shares of Arecor Therapeutics? Shares of AREC stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock. What other stocks do shareholders of Arecor Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Arecor Therapeutics investors own include Pfizer (PFE), NVIDIA (NVDA), PayPal (PYPL), Advanced Micro Devices (AMD), Cisco Systems (CSCO), Lowe's Companies (LOW) and SNDL (SNDL). Company Calendar Last Earnings4/22/2025Today5/10/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeLON SectorMedical Industry Biotechnology Sub-IndustryCoal Current SymbolLON:AREC CIKN/A Webwww.americanresourcescorp.com Phone44 1223 426 060FaxN/AEmployees10Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)GBX (28.30) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income£-10,683,346.07 Net Margins-176.89% Pretax MarginN/A Return on Equity-118.67% Return on Assets-37.31% Debt Debt-to-Equity Ratio5.51 Current Ratio1.37 Quick Ratio6.24 Sales & Book Value Annual Sales£6.04 million Price / Sales2.44 Cash FlowGBX 7.71 per share Price / Cash Flow5.07 Book ValueGBX 16.58 per share Price / Book2.36Miscellaneous Outstanding Shares37,756,599Free FloatN/AMarket Cap£14.76 million OptionableNot Optionable Beta-0.18 7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.Get This Free Report This page (LON:AREC) was last updated on 5/10/2025 by MarketBeat.com Staff From Our PartnersGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredTrump’s Bitcoin Reserve is No Accident…Remember when they said crypto would never go mainstream? Well, something remarkable has happened… Blac...Crypto 101 Media | SponsoredTrump’s Secret WeaponWall Street is nervous. Billionaires are shifting assets. And everyday investors? Most are completely unprepa...American Alternative | Sponsored[FREE GIFT] New AI for retail tradersTradeAlgo has found a “backdoor way” for retail traders to profit from the AI arms race by developing its grou...TradeAlgo | SponsoredOne Stock Gold Blueprint to Survive the Market ChaosOne Stock Gold Blueprint to Survive the Market Chaos Markets are volatile, uncertainty is everywhere, and A...InvestorPlace | SponsoredThe one deadline Elon can't afford to miss...For years, Elon Musk made headlines for blowing past deadlines — so often that investors coined a nickname for...Brownstone Research | SponsoredNew breed of trader (Wall Street hates us?)Wall Street big wigs and old-money bankers can’t touch this 1 type of stock. And that opens the door for tr...Timothy Sykes | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Arecor Therapeutics plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Arecor Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.